VivoSeq
Other

EEG

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

EEG is an early-stage landscape with 0 programs across 1 company. The most active players are Merck & Co..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

33/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Withdrawn1 · 25%
Completed1 · 25%
Terminated1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Roflumilast TMS-EEG Plasticity
Withdrawn·UUniversity of Calgary·Phase 1·NCT04369547
EEG (Electroencephalogram) Platform Standardization in Healthy Male Subjects (3134-010)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT01110616·25 enrolled
Lacosamide IV and EEG/EKG (LIVE) Study
Terminated·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 2·NCT01724918·72 enrolled
EEG Microstates Across At-Risk Mental States
Recruiting·—·N/A·NCT06045897·126 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)